September 18, 2025Open Access
View Full PaperSupplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Key Points
- The study focuses on drug exposure and follow-up duration for zilovertamab vedotin.
- Participants included individuals diagnosed with metastatic solid tumors.
- The follow-up duration was essential to assess the ongoing effects of the treatment.
- Understanding this data may guide future treatment protocols for metastatic tumors.
Abstract
Supplemental Table S3. Study Drug Exposure and Follow-Up Duration
Cite This Study
Meric‐Bernstam et al. (Wed,) studied this question.